Journal
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
Volume -, Issue -, Pages -Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/17512433.2023.2277330
Keywords
Angiotensinogen; angiotensin II; drug adherence; GalNAc; hypertension therapy; nonadherence; renin-angiotensin system; siRNA
Categories
Ask authors/readers for more resources
Hypertension is a major risk factor for cardiovascular disease worldwide. Nonadherence to medication is a significant issue in hypertension treatment. Small interfering RNA therapy targeting hepatic angiotensinogen offers durability and liver-specificity, making it a potential precision medicine approach for hypertension.
IntroductionHypertension is the main global risk factor for cardiovascular disease. Despite this, less than half of treated hypertensive patients are controlled. One reason for this is nonadherence, a major unmet need in hypertension pharmacotherapy. Small interfering RNA (small interfering ribonucleic acid) therapies inhibit protein translation, and, when linked to N-acetylgalactosamine, allow liver-specific targeting, and durability over several months. Targeted knockdown of hepatic angiotensinogen, the source of all angiotensins, offers a precision medicine approach.Areas coveredThis article describes the molecular basis for durability over months and the 24-h tonic target inhibition observed after one administration. We present an analysis of the published phase I trials using zilebesiran, a siRNA targeting hepatic angiotensinogen, which reduces blood pressure (BP) by up to 20 mmHg, lasting 24 weeks. Finally, we examine data evaluating reversibility of angiotensinogen knockdown and its relevance to the future clinical utility of zilebesiran.Expert opinionFurther studies should assess safety, efficacy, and outcomes in larger, more broadly representative groups. An advantage of zilebesiran is the potential for bi-annual dosing, thereby reducing nonadherence and improving control rates. It may also reduce nighttime BP due to 24-h tonic control. The provision of adherence assessment services will maximize the clinical value of zilebesiran.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available